Literature DB >> 29566367

Defective Circulating Regulatory B Cells in Patients with Dilated Cardiomyopathy.

Jiao Jiao, Yu-Zhi Lu, Ni Xia, Yi-Qiu Wang, Ting-Ting Tang, Shao-Fang Nie, Bing-Jie Lv, Ke-Jing Wang, Shuang Wen, Jing-Yong Li, Xing-Di Zhou, Yu-Hua Liao, Xiang Cheng.   

Abstract

BACKGROUND/AIMS: Newly identified IL-10-producing regulatory B cells (Bregs) have been shown to play an important role in the suppression of immune responses. Chronic immune activation participates in the pathogenesis of dilated cardiomyopathy (DCM) but whether Bregs are involved in its development remains unclear. We aimed to investigate the circulating frequency and function of Bregs in DCM.
METHODS: In total, 35 DCM patients (20 men and 15 women) and 44 healthy controls (23 men and 21 women) were included in the experiment, and the frequency of Bregs was detected using flow cytometry.
RESULTS: According to our results, the frequency of circulating IL-10-producing Bregs was significantly lower in DCM patients compared with healthy controls. Furthermore, the CD24hiCD27+ B cell subset in which IL-10-producing Bregs were mainly enriched from DCM patients showed impaired IL-10 expression and a decreased ability to suppress the TNF-α production of CD4+CD25- Tconv cells and to maintain Tregs differentiation. Correlation analysis showed that the frequency of IL-10-producing Bregs and the suppressive function of CD24hiCD27+ B cells were positively correlated with left ventricular ejection fraction and negatively correlated with NT-proBNP in DCM patients.
CONCLUSIONS: In conclusion, the reduced frequency and impaired functions suggest a potential role of Bregs in the development of DCM.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  CD24hiCD27+ B cell; Dilated Cardiomyopathy (DCM); Regulatory B cell (Breg)

Mesh:

Substances:

Year:  2018        PMID: 29566367     DOI: 10.1159/000488405

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  7 in total

Review 1.  The Role of B Cells in Cardiomyopathy and Heart Failure.

Authors:  Kevin Bermea; Aashik Bhalodia; Angelo Huff; Sylvie Rousseau; Luigi Adamo
Journal:  Curr Cardiol Rep       Date:  2022-06-11       Impact factor: 3.955

2.  Ex vivo characterization of Breg cells in patients with chronic Chagas disease.

Authors:  Magalí C Girard; Gonzalo R Acevedo; Micaela S Ossowski; Marisa Fernández; Yolanda Hernández; Raúl Chadi; Karina A Gómez
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379

Review 3.  Regulatory T Cells in Chronic Heart Failure.

Authors:  Yuzhi Lu; Ni Xia; Xiang Cheng
Journal:  Front Immunol       Date:  2021-09-22       Impact factor: 7.561

4.  The abnormal distribution of peripheral B1 cells and transition B cells in patients with idiopathic dilated cardiomyopathy: a pilot study.

Authors:  Quan Tang; Zhihong Cen; Jing Lu; Jingwei Dong; Lin Qin; Feiyu Lu; Weifeng Wu
Journal:  BMC Cardiovasc Disord       Date:  2022-03-04       Impact factor: 2.298

Review 5.  Immunomodulatory Treatment Strategies Targeting B Cells for Heart Failure.

Authors:  Xinxin Zhang; Yuxi Sun; Ning Wang; Yanli Zhang; Yunlong Xia; Ying Liu
Journal:  Front Pharmacol       Date:  2022-03-08       Impact factor: 5.810

6.  Integrated Bioinformatics Algorithms and Experimental Validation to Explore Robust Biomarkers and Landscape of Immune Cell Infiltration in Dilated Cardiomyopathy.

Authors:  Qingquan Zhang; Mengkang Fan; Xueyan Cao; Haihua Geng; Yamin Su; Chunyu Wu; Haiyan Pan; Min Pan
Journal:  Front Cardiovasc Med       Date:  2022-04-01

Review 7.  The role of B cells in heart failure and implications for future immunomodulatory treatment strategies.

Authors:  Gerardo García-Rivas; Elena Cristina Castillo; Adrian M Gonzalez-Gil; José Luis Maravillas-Montero; Marion Brunck; Alejandro Torres-Quintanilla; Leticia Elizondo-Montemayor; Guillermo Torre-Amione
Journal:  ESC Heart Fail       Date:  2020-06-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.